Smacking ban is needed to protect children, health experts say
Experts from a number of medical specialties, including children's doctors and psychiatrists, said that decades of research shows the 'detrimental effects of physical punishment'.
According to the Children Act 2004, it is unlawful to hit your child, except where it is 'reasonable punishment', and this is judged on a case-by-case basis.
But experts said these laws are 'vague and dangerous'.
Now 13 health organisations are calling on the Government to back an amendment to the Children's Wellbeing and Schools Bill which would remove the 'reasonable punishment' defence from law in England.
They said that the Bill reaching committee stage in the House of Lords is a 'pivotal moment' in the smacking ban campaign.
Baroness Finlay has proposed an amendment to eliminate the 'reasonable punishment' defence.
In an open letter, the organisations said this defence is 'archaic' and 'allows for the physical punishment of children'.
'This leaves them with less protection from assault than adults, an unacceptable disparity in our modern society,' they wrote.
'The evidence is clear: physical punishment is harmful, ineffective, and has no place in a society that values the well-being of its children.'
The organisations called on the Government to 'stand on the side of our children and ensure their fundamental right to safety and protection', adding: 'By removing this archaic defence, we can send a clear message that violence against children is never acceptable.'
Professor Andrew Rowland, child protection officer at the Royal College of Paediatrics and Child Health and a consultant paediatrician, said: 'There is now strong agreement from health and social care professionals that the current laws around physical punishment of children, including smacking, are unjust, vague and ultimately dangerous.
'It is time to bring protection from physical assault for children in line with the protection afforded to adults.
'Every child deserves the best possible start to life, and eradicating physical punishment of children is a key part of that aim.'
Dr Elaine Lockhart, head of the Child and Adolescent Faculty at the Royal College of Psychiatrists, added: 'The physical punishment of children is not just cruel, it is dangerous: the practice has been shown to be detrimental to children's mental health and leads to poor developmental outcomes.'
Dr Tamasin Knight, from the British Medical Association's public health medicine committee, added: 'We believe that children should have full legal protection from all forms of physical punishment.'
The full list of signatories on the letter are: Royal College of Paediatrics and Child Health; Faculty of Public Health; Royal Society of Medicine; School and Public Health Nurses Association; Institute of Health Promotion and Education; Institute of Health Visitors; Royal Society for Public Health; British Association for Child and Adolescent Public Health; British Medical Association; Royal College of Psychiatrists; Aldey Hey Hospital Charity; Alliance 4 Children and Barnardo's.
The Government has been approached for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
2 hours ago
- Washington Post
Government's demand for trans care info sought addresses, doctors' notes, texts
The Justice Department is demanding that hospitals turn over a wide range of sensitive information related to medical care for young transgender patients, including billing documents, communication with drug manufacturers and data such as patient dates of birth, Social Security numbers and addresses, according to a copy of a subpoena made public in a court filing this week.
Forbes
4 hours ago
- Forbes
What Is Your Health Record Worth? The Unseen Economics Behind Your Medical Data
Two thousand years ago, physicians in Egypt documented their patients' symptoms and treatments on papyrus scrolls. These early medical records served a simple, localized purpose: they supported direct care, were referenced in case discussions, and played a role in medical education. For most of human history, medical documentation was a tool for the physician, with little utility beyond the immediate circle of care. But in the modern era, as records have gone digital, they have transformed into something else entirely: a commodity. Today, medical records are exchanged, aggregated, analyzed, and monetized at a scale unimaginable in the paper era. Governments, researchers, and corporations alike are tapping into their value. Yet, for all the headlines about billion-dollar data deals and the promise of AI-driven breakthroughs, the average American remains largely unaware of what their medical data is worth—or how little control they have over it. In fact, the reality of the health data economy may surprise many. While one survey suggests that 70% of Americans would only be willing to share their records for more than $1,000, the actual price those records fetch is often far lower. For instance, despite claims that hackers can sell health data for $250 per record, consider last year's Change Healthcare hacking episode. A security breach compromised the data of over 190 million Americans at the company, which is a UnitedHealth Group subsidiary. UnitedHealth Group reportedly paid the hackers $22 million in ransom—an implicit valuation of just 11.5 cents per record. More challenging still, individuals are rarely in a position to benefit from the emerging market for health data in any meaningful way. The Evolution of the Medical Record Historically, the medical record was a tool of practice and pedagogy. In the 19th and 20th centuries, hospitals and teaching institutions developed increasingly sophisticated case files, supporting diagnoses, treatments, and post-mortem reviews. But the paper record had limits: it was static, siloed, and difficult to scale. Its value was largely confined to the provider who created or maintained it. This began to change with the advent of electronic health records (EHRs), especially following the 2009 enactment of the HITECH Act as part of the American Recovery and Reinvestment Act. The federal government allocated billions to incentivize the adoption of EHR systems, explicitly aiming to create a "learning healthcare system" that could generate insights from aggregated clinical data. Digitization brought tremendous promise. Actual medical records, with discrete and detailed clinical data, could now be searched, shared, and studied. Health systems could coordinate care more effectively. Researchers could analyze trends across populations. And during the COVID-19 pandemic, the ability to report and track public health data in real time became critically important. But digitization also created new opportunities—and incentives—for data monetization. Who Buys Health Data, and Why? Health data is now big business, with most estimates pegging the market between $2B and $8B. And for good reason: the ability for researchers to investigate vast de-identified digitized datasets to understand how both individuals and therapies behave and respond in the real world (known as Real World Data or RWD), versus the rigid confines of clinical trials, holds the promise of increasing the pace and lowering the cost of medical discovery. In many ways, de-identified health data is nothing new: researchers and others have had access to some data for decades, thanks to medical claims data created by billing and reimbursement between providers and health plans. Claims data, however, can be thought of as a mile wide, an inch deep: it can tell the journey of patients, but isn't sharp on the details. What is new, then, is the depth and robustness of health records themselves: clinical notes, lab values, procedures, outcomes, etc. Pharmaceutical companies now buy RWD to identify candidates for clinical trials and assess treatment effectiveness. Health insurers analyze it to manage costs and stratify patient risk. Startups and AI firms use it to train algorithms, while public health agencies rely on it to monitor disease patterns. Despite these widespread uses, there's still little transparency around what health records are actually worth. That question is further complicated by ethical and legal considerations, which shape not only the price of data but who gets to profit from it. The Ethics and Regulation of Health Data Sharing A recent glaring example of the public's unease with health data and big tech is the story of Project Nightingale. In 2019, Google and Ascension Health launched a partnership to analyze millions of patient records. Both organizations acted within legal boundaries: HIPAA allows patient data sharing for treatment, payment, and healthcare operations purposes. Nonetheless, a whistleblower raised concerns, and public backlash was swift. Critics argued that the scale of the data sharing and the lack of transparency violated patient trust. Healthcare data can be used for other purposes (including research, analytics and/or commercial purposes), but must first be deidentified. The process of deidentification, defined by HIPAA, requires the removal of 18 types of identifiers or an expert determination that the risk of reidentification is very low. But deidentification isn't foolproof, especially with advanced re-identification techniques. And even when the rules are followed, public sentiment may differ from regulatory interpretations. The Project Nightingale controversy illustrates a central tension: legal permissibility does not always equate to ethical acceptability. As data sharing scales and becomes more commercialized, that distinction becomes increasingly salient. What Does The Data Say About The Value Of Health Data? So what is the value of a medical record? According to conversations with several industry experts, the answer depends on several factors. And for people interested in the value of their own health data, it may be disappointing. In general, records of healthy individuals or those with common, well-managed conditions tend to be worth very little. Their data is often less useful for clinical research, predictive modeling, or training AI models. On the other hand, records associated with specific diseases, especially rare or complex conditions, can command far higher value. This is particularly true when the data includes structured lab results, imaging, medication histories, and genomic information. For example, primary care records may be valued as low as 50 cents per patient. Medical imaging data (from MRIs, CT scans, ultrasounds or X-rays) may be worth $30, depending on the underlying medical condition, purpose and location of the scan. In contrast, oncology medical records can be worth between $950 and $2,000 per patient, and genomic data alone can command $1,700 to $5,000. When genomic data is linked with phenotypic data, a combination prized by precision medicine companies, the value can exceed $6,000. Also worth noting is that these figures tend to represent value, not prices. Value in this context refers to the revenue a record holder can generate over time from selling data to multiple customers, rather than the price they might get from an individual buyer. For instance, while Tempus AI, a genomic lab company, realized an average of $1,899 in revenue per de-identified record, this was over a five year time horizon. Further data from Tempus suggests that health data may be subject to normal economic laws: as supply increases, prices may come down. Its revenue generated per record for new patients has decreased over successive years, from $502 per record in 2019 to $128 per record in 2023 (based on the author's firm's analysis). Further, the price a data broker or pharmaceutical company is willing to pay varies depending on the specific use case they are focused on, the supply and availability of similar data, and the ease of acquisition. Why It's Not Easy To Cash In There are several reasons why individual Americans can't easily profit from the value of their health data. First, while federal law (via HIPAA) guarantees a right of access to one's medical records, most patients do not have a comprehensive or consolidated copy. Health data is often fragmented across hospitals, clinics, pharmacies, labs, and insurers. Second, even with digital access, which most providers are now enabled (and effectively mandated) to make available, individual patients lack the market power or technical means to sell their data. The demand side of the data economy (e.g., pharmaceutical companies) generally needs hundreds or thousands (or more) records to suit their research purposes. Aggregated datasets are more valuable and easier to use than individual records. As a result, natural aggregators like hospitals, health systems, and EHR vendors are better positioned to meet that demand. Third, most individuals lack the necessary tools to de-identify their data or license it for specific purposes. While some technology companies are attempting to create platforms for personal data monetization, these remain nascent and face significant adoption and regulatory hurdles. There are companies out there seeking to change this paradigm. San Francisco-based Evidation Health has raised hundreds of millions of dollars to create a technology platform to help consumers aggregate their health and wellness data and enable them to participate in sponsored research. 'Individuals' data has value, and we believe they should share in that value,' notes Evidation's CEO Leslie Oley Wilberforce. Despite Evidation's progress - the company raised more capital in 2024 to accelerate growth - consumer awareness and adoption of these types of platforms remains nascent. The result is a market that extracts value from consumers without empowering them to participate. Americans may believe their data is worth hundreds of dollars, but without access, infrastructure, or market presence, they remain on the outside looking in. Case Study: 23andMe Perhaps no example better encapsulates the promise and peril of consumer health data than 23andMe. Once a darling of the direct-to-consumer genomics boom, the company amassed genetic data from more than 15 million people. It offered inexpensive at-home DNA tests, promising ancestry insights and health risk predictions. But the real business model was always data. 23andMe struck multiple deals with pharmaceutical companies, including a major collaboration with GlaxoSmithKline. These agreements were designed to monetize its enormous trove of genomic and phenotypic data for drug discovery and clinical research. Yet by 2025, the company had filed for Chapter 11 bankruptcy. Just weeks later, it was acquired by Regeneron for a mere $256 million—a dramatic fall from its $6 billion valuation just a few years prior. The decline was accelerated by a 2023 data breach affecting 6.9 million users, and growing public unease over privacy practices. The 23andMe story is a cautionary tale. Consumers willingly handed over their most intimate biological data, only to see that data become an asset in corporate transactions they had no control over. Even if Regeneron maintains 23andMe's stated privacy policies, the legal and ethical framework governing genetic data in the U.S. remains weak and fragmented. Conclusion: A Market With Limited Participation We began this story on papyrus scrolls, when medical records served the care of a single person and had little value beyond their immediate use. Today, we live in an age where those records are digitized, replicated, analyzed, and sold, often without the knowledge or benefit of the people to whom they pertain. So what is your health data worth? The disappointing answer is: it depends, but don't quit your day job, because you likely can't capitalize on it yet anyway. As the health data economy matures, we must grapple with fundamental questions: Who benefits? Who decides how data is used? And how can patients be treated not just as data points, but as participants in a system built on their personal information? In the next article in this series, we'll explore how health data is actually priced: who pays what, for which kinds of data, and what that tells us about the real value of your medical record.
Yahoo
11 hours ago
- Yahoo
UAE Health Insurance Market Size, Share, Trends and Forecast by Type and Service Provider 2025-2033
Factors driving growth include mandatory insurance laws, rising private healthcare demand, and digitalization. Government initiatives and expatriate influx further boost market expansion. UAE Health Insurance Market Dublin, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The "UAE Health Insurance Market Size, Share, Trends and Forecast by Type, and Service Provider, 2025-2033" has been added to offering. The UAE health insurance market size was valued at USD 8.72 Billion in 2024. Projections indicate growth to USD 14.9 Billion by 2033, with a CAGR of 6.1% between 2025-2033. This growth is fueled by mandatory insurance regulations in Emirates like Abu Dhabi and Dubai, heightened demand for private healthcare services, and increasing awareness of health risk protection. In parallel, factors such as population growth, an influx of expatriates, enhanced government investment in healthcare infrastructure, digitalization of insurance services, and improved consumer awareness are expanding the UAE health insurance market share. In the UAE, the rising prevalence of chronic diseases is another market catalyst. The steady influx of expatriates and foreign workers has spurred demand for health insurance because UAE employers are often mandated to provide coverage, attracting global insurance providers to this dynamic market. Technological advancements, especially the adoption of digital insurance platforms, have amplified accessibility and user convenience, further driving the market's growth. Moreover, educational campaigns have substantially raised awareness and understanding of health insurance benefits within the UAE populace. UAE Health Insurance Market Trends/Drivers Increasing government initiatives The UAE government actively enhances healthcare accessibility and affordability via regulations and mandates. Compulsory employer-provided insurance has broadened insurance coverage across the population, catalyzing a rise in demand for health plans nationwide. Concurrently, government efforts to bolster healthcare infrastructure, integrate advanced medical technologies, and promote medical tourism enhance the market outlook. These initiatives aim to enrich the overall healthcare ecosystem, indirectly strengthening the health insurance sector. Additionally, government-led educational campaigns underscore the significance of health insurance, facilitating market expansion. Rising healthcare expenditure Escalating healthcare costs are a significant market driver. With healthcare expenses rising, individuals and businesses increasingly seek financial protection, boosting demand for insurance that mitigates medical costs. Leading insurers are broadening coverage and benefits to ensure comprehensive access to quality medical services and exploring innovative reimbursement models like value-based care. UAE Health Insurance Industry Segmentation The market analysis addresses key trends and provides forecasts at the country level from 2025-2033, categorized by type and service provider. Breakup by Type: Individual Group The group type dominates, catering to organizations and associations with varied benefits, offering cost-effective options tailored to group-specific needs. Meanwhile, individual plans empower personal choice with diverse coverage levels and benefits, aligning with individual healthcare requirements and budgets. Breakup by Service Provider: Public Private The private sector commands the majority market share, offering diverse insurance plans with improved service quality through technological investments. Private insurers enhance customer experience through efficient claims processing and personalized support. Conversely, the public sector emphasizes equitable coverage, ensuring accessible healthcare across the UAE. Competitive Landscape Key market players innovate to meet evolving consumer and business demands, implementing digital solutions for policy management, claims submission, and telemedicine. They also expand healthcare provider networks and introduce specialized insurance products, ensuring comprehensive service to match the diverse needs of the market. Key Questions Answered in This Report: How big is the health insurance market in UAE? What factors are driving the growth of the UAE health insurance market? What is the forecast for the health insurance market in UAE? Which segment holds the largest UAE health insurance type market share? Key Attributes Report Attribute Details No. of Pages 121 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $8.7 Billion Forecasted Market Value (USD) by 2033 $14.9 Billion Compound Annual Growth Rate 6.1% Regions Covered United Arab Emirates Key Topics Covered1 Preface2 Scope and Methodology2.1 Objectives of the Study2.2 Stakeholders2.3 Data Sources2.4 Market Estimation2.5 Forecasting Methodology3 Executive Summary4 Introduction4.1 Overview4.2 Key Industry Trends5 UAE Health Insurance Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Breakup by Type5.5 Market Breakup by Service Provider5.6 Market Forecast5.7 SWOT Analysis5.8 Value Chain Analysis5.9 Porter's Five Forces Analysis5.10 PESTEL Analysis5.11 Price Analysis6 Market Breakup by Type6.1 Individual6.2 Group7 Market Breakup by Service Provider7.1 Public7.2 Private8 Government Regulations9 Strategic Recommendations10 Competitive Landscape10.1 Market Structure10.2 Key Players10.3 Profiles of Key PlayersFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment UAE Health Insurance Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
